Petosemtamab manufacturers
- Petosemtamab
-
- $355.00
-
2026-07-27
- CAS:2213450-26-9
- Purity: > 95%
- Supply Ability: 10g
|
| | Petosemtamab Basic information |
| Product Name: | Petosemtamab | | Synonyms: | Petosemtamab;Research Grade Petosemtamab (DHB86918);MCLA 158;Research Grade Petosemtamab | | CAS: | 2213450-26-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Petosemtamab Structure]() |
| | Petosemtamab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Petosemtamab Usage And Synthesis |
| Uses | Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2]. | | in vivo | MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2].
| Animal Model: | Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2] | | Dosage: | 25 mg/kg/week | | Administration: | Intravenous injection (i.v.) for 6 weeks. | | Result: | Inhibited tumor growth. |
| | IC 50 | EGFR: 0.22 nM (Kd); LGR5: 0.85 nM (Kd) | | References | [1] Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.
[2] Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl |
| | Petosemtamab Preparation Products And Raw materials |
|